



PATENT Attorney Docket No. 056291-5245

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BARLAAM et al.	)
Application No.: 10/572,794	) Group Art Unit: 1624
Filed: March 21, 2006	) Examiner: Unassigned
For: QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS	) Date: April 20, 2007

Commissioner for Patents U.S. Patent and Trademark Office Customer Window, Mail Stop Amendment Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Date: April 20, 2007 Morgan Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 By:

Donald J Bird Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

Respectfully Submitted, Morgan Lewis & Bock

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)  PTO Form 1449 April 20, 2007			Attorney Docket No. 056291-5245 Application No. 000772,794					
			Applicants: BARLAAM et a APR 20 1001 Filing Date: March 21, 2006 Franch Croup Art Unit: 1624					
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date	
	-							
	_					<del>  </del>		
						T		
ALL	REFE	RENCES CONSIDE		IERE LINED THRO PATENT DOCUME				
		Document No.	Date	Country		Sub-Class	Translation	
	1.	DE 10040527	February 28, 2003				Claims	
	2.	WO 00/09481	February 24, 200				Claims	
	3.	WO 02/062767	August 15, 2002	WIPO			Claims	
AH BI	FFRI	ENCES CONSIDER	ED EXCEPT WHE	<del>RELINED THROH</del>	GH /TN/	1		
				ling Author, Title, Da		mes etc.)		
	4.	Ballard et al. "Inhibite	ors of enidermal grow	th factor recentor tyro	sine kinase: Nove	d C-5 enhetitu	ted	
	i	anilinoquinazolines de						
		Ballard et al. "5-Subst	ituted 4-anilinoquina	inazolines as potent, selective and orally active inhibitors of erbB2 receptor				
		tyrosine kinase" Bioorg Med Chem Lett. 15(19):4226-4229 (2005)						
		Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics" Bioorg Med Chem Lett. 16(18):4908-4912 (2006)						
	<ol> <li>Harris et al. "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core" letters 46(43): 7381-7384 (2005).</li> </ol>							
	8.	Harris et al. "Selective	alkylation of a 6.7-d	ihydroxyguinazoline"	Tetrahedron lette	rs 46(45):771	5-7719 (2005)	
		Hennequin et al. "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors" Bioorg Med Chem Lett.						
	16(10):2672-2676 (2006) .							
ALL	here	RENCES CONSIDE	RED EXCEPT WI	IERE LINED THRO	HGH. /T.N./			
	-	ı						
xaminer		/Tamthom Tr	Data C	Considered				